Figure 7. CD32B antigen modulation following antibody treatment in vitro and in vivo. (A) Daudi cells were cultured in the presence of ch2B6 (1 μg/mL) or hu2B6-3.5 (1 μg/mL) for 24 hours and analyzed for expression of CD32B or the presence of anti-CD32B antibodies, at the indicated time points. (B) Residual Daudi tumors, treated with 8 weekly doses of hu2B6-3.5 (25 μg/mouse), rituximab (25 μg/mouse), or PBS were allowed to grow in vivo for an additional week. Tumors were removed, dissociated, and incubated with the following antibodies (1-2 μg/mL): anti–CD32B-FITC (2B6, bold line), anti–CD20-FITC (L27, dotted line), or murine IgG1-FITC (solid area). The anti-CD32B (2B6) and anti-CD20 (L27) antibodies used do not cross-react with the corresponding mouse antigens.
Figure 7.

CD32B antigen modulation following antibody treatment in vitro and in vivo. (A) Daudi cells were cultured in the presence of ch2B6 (1 μg/mL) or hu2B6-3.5 (1 μg/mL) for 24 hours and analyzed for expression of CD32B or the presence of anti-CD32B antibodies, at the indicated time points. (B) Residual Daudi tumors, treated with 8 weekly doses of hu2B6-3.5 (25 μg/mouse), rituximab (25 μg/mouse), or PBS were allowed to grow in vivo for an additional week. Tumors were removed, dissociated, and incubated with the following antibodies (1-2 μg/mL): anti–CD32B-FITC (2B6, bold line), anti–CD20-FITC (L27, dotted line), or murine IgG1-FITC (solid area). The anti-CD32B (2B6) and anti-CD20 (L27) antibodies used do not cross-react with the corresponding mouse antigens.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal